ArticleAnnals of hematology2023

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.

Shenmiao Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.